苑东生物: 苑东生物：第四届董事会第七次会议决议公告

Meeting Overview - The fourth board meeting of Chengdu Yuandong Biopharmaceutical Co., Ltd. was held on August 18, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the half-year report and its summary for 2025, with a unanimous vote of 9 in favor [2][3]. - The board also approved a special report on the management and actual use of raised funds for the first half of 2025, confirming compliance with legal requirements and proper decision-making procedures [2][3]. - A report on the mid-year evaluation of the "Quality Improvement and Efficiency Recovery Action Plan for 2025" was also approved unanimously [3]. - The board agreed to postpone certain fundraising investment projects, stating that the decision was made based on practical circumstances and would not adversely affect normal operations [3][4]. - An agreement related to the production information system with a related party was approved, emphasizing the necessity of digital and intelligent management in the pharmaceutical industry [4].